The report provides a detailed analysis essential for establishing a Lazertinib production plant. It encompasses all critical aspects necessary for Lazertinib production, including the cost of Lazertinib production, Lazertinib plant cost, Lazertinib production costs, and the overall Lazertinib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Lazertinib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Lazertinib is an anticancer drug primarily used in the treatment of non-small cell lung cancer (NSCLC). It is primarily utilised as a targeted therapy for patients with non-small cell lung cancer (NSCLC) that carries specific mutations in the epidermal growth factor receptor (EGFR) gene. The compound acts by blocking the activity of EGFR, which helps slow down or stop the growth of cancer cells.
It is often utilised as a targeted therapy in advanced or metastatic stages of lung cancer to provide better treatment outcomes with fewer side effects compared to conventional chemotherapy. Moreover, Lazertinib is often used in combination with other anticancer drugs to enhance treatment outcomes and reduce resistance. It also serves as an important compound in modern oncology and research for developing new therapies that improve the survival rate and quality of life of cancer patients.
The market for Lazertinib is predominantly driven by its application as an anticancer drug for the treatment of non-small cell lung cancer (NSCLC), which promotes its demand in the pharmaceutical industry. Its usage as a targeted therapy for advanced or metastatic lung cancer further fuels its demand in oncology therapeutics. Moreover, ongoing research activities and clinical trials for exploring its potential in combination therapies for resistant cancer types also enhance its demand in clinical and pharmaceutical research sectors.
Additionally, factors such as the availability and cost of active pharmaceutical ingredients, regulatory compliance, and advancements in cancer treatment technologies play a crucial role in influencing industrial Lazertinib procurement globally. Manufacturing standards, supplier reliability, efficient logistics, and evolving healthcare infrastructure are also some of the major factors that further contribute to shaping market trends and supply dynamics.
Raw Material for Lazertinib Production
According to the Lazertinib production plant project report, the major raw materials for Lazertinib production include Aryl fluoride- Morpholine- 3-Chloropropionyl chloride - Methyl sulfone derivative.
Production Process of Lazertinib
The extensive Lazertinib production cost report consists of the following industrial production process:
- Production via Condensation: The production process of Lazertinib begins with a nucleophilic aromatic substitution (SNAr) reaction between an aryl fluoride compound and morpholine to form the first intermediate. Then, the aniline nitrogen in this intermediate is formylated to protect it before the nitro group is reduced, giving a secondary aniline derivative. Further, the compound is next acylated using 3-chloropropionyl chloride, followed by a base-catalysed elimination that produces an acrylate intermediate. Then, the N-formanilide portion of this molecule is deprotonated and reacts with a methyl sulfone compound, which couples the two fragments together. Further treatment with aqueous sodium hydroxide removes the N-formyl group and produces an aminopyrimidine acrylate intermediate. Finally, a dimethylamino group is introduced through a STAB-H–mediated reductive amination step, which leads to the production of Lazertinib in high yield and purity.
Lazertinib is an antineoplastic compound that appears as a white to pale yellow crystalline solid. It is an odourless compound, which is practically insoluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. The molecular formula of lazertinib is C27H27FN6O2, and its molar mass is 486.54 g/mol. The compound has a melting point in the range of 214–216 degree Celsius. Lazertinib is chemically stable under dry, normal storage conditions but may degrade when exposed to moisture, heat, or direct sunlight. It belongs to the class of tyrosine kinase inhibitors and selectively targets mutant epidermal growth factor receptor (EGFR) enzymes. The compound should be handled with care, as it may cause irritation upon contact and should be stored in a tightly closed container at controlled room temperature.
